Cargando…
Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242627/ https://www.ncbi.nlm.nih.gov/pubmed/36745098 http://dx.doi.org/10.1182/bloodadvances.2023009864 |
| _version_ | 1785054258120359936 |
|---|---|
| author | Potnis, Kunal C. Huntington, Scott F. |
| author_facet | Potnis, Kunal C. Huntington, Scott F. |
| author_sort | Potnis, Kunal C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10242627 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102426272023-06-07 Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma Potnis, Kunal C. Huntington, Scott F. Blood Adv Response The American Society of Hematology 2023-02-09 /pmc/articles/PMC10242627/ /pubmed/36745098 http://dx.doi.org/10.1182/bloodadvances.2023009864 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Response Potnis, Kunal C. Huntington, Scott F. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title | Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title_full | Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title_fullStr | Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title_full_unstemmed | Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title_short | Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| title_sort | balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma |
| topic | Response |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242627/ https://www.ncbi.nlm.nih.gov/pubmed/36745098 http://dx.doi.org/10.1182/bloodadvances.2023009864 |
| work_keys_str_mv | AT potniskunalc balancingconsiderationsandqualifyingconclusionsforcosteffectivenessoftherapiesforrelapsedrefractoryfollicularlymphoma AT huntingtonscottf balancingconsiderationsandqualifyingconclusionsforcosteffectivenessoftherapiesforrelapsedrefractoryfollicularlymphoma |